Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-alpha have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects?

F. de' Clari,I. Salani,E. Safwan,A. Giannacco
DOI: https://doi.org/10.1161/01.CIR.0000017216.41471.DF
IF: 37.8
2002-05-28
Circulation
Abstract:To the Editor: A phase II study to assess the side effects of Remicade (infliximab) in patients with cardiac insufficiency NYHA III-IV revealed 7 deaths due to worsening of cardiac insufficiency among 150 patients who had received 3 infusions of Remicade of either 5 mg/kg or 10 mg/kg. The pharmaceutical company warned doctors not to give Remicade to patients with heart insufficiency of the class NYHA III-IV. We report a case of sudden death 18 hours after a single infusion of Remicade in a patient without heart insufficiency. The patient, a 64-year-old man with classical rheumatoid arthritis refractory to antiinflammatory and immunosuppressive treatment (he had received hydroxychloroquine, methotrexate, leflunomide, deflazacort, oral corticosteroids, and AINS) accepted to try infliximab, a monoclonal antibody inhibiting the biological activity of tumor necrosis factor-α (TNF-α). The patient complained of pain in the joints and shoulders, morning stiffness, fatigue, and depression. He had a bicameral pacemaker implanted in 1994 for bradycardia but had neither anamnestic …
What problem does this paper attempt to address?